SCHEMBL16655740

SCHEMBL16655740

COc1c(Cl)ccc(-c2nn(C3Cc4ccccc4C3)c3ncnc(N)c23)c1Cl

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BTK Q06187 13/20 0.61
PIK3CD O00329 13/20 0.61
ATR Q13535 6/20 0.52
NUDT14 O95848 1/20 0.45
NUDT5 Q9UKK9 1/20 0.45
RET P07949 1/20 0.45
ABL1 P00519 1/20 0.45
EGFR P00533 1/20 0.45
HCK P08631 1/20 0.45
SRC P12931 1/20 0.45
KDR P35968 1/20 0.45
PIK3CA P42336 1/20 0.45
PIK3CB P42338 1/20 0.45
MTOR P42345 1/20 0.45
PIK3CG P48736 1/20 0.45
EPHB4 P54760 1/20 0.45
PRKDC P78527 1/20 0.45
PI4KB Q9UBF8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL23908600 0.99 BTK (0.60) BTKPIK3CDATRNUDT14NUDT5
SCHEMBL16655723 0.85 PIK3CD (0.67) BTKPIK3CDATRABL1EGFR
SCHEMBL16655375 0.82 PIK3CD (0.68) BTKPIK3CDATRABL1EGFR
SCHEMBL16655806 0.80 PIK3CD (0.67) BTKPIK3CDATRABL1EGFR
SCHEMBL16665825 0.79 PIK3CD (0.43) BTKPIK3CDABL1EGFRHCK
SCHEMBL16655400 0.78 PIK3CD (0.75) BTKPIK3CDATRABL1EGFR
Hydrochloric Acid SCHEMBL23908604 0.77 PIK3CD (0.74) BTKPIK3CDATRABL1EGFR
SCHEMBL16655491 0.77 PIK3CD (0.64) BTKPIK3CDATRABL1EGFR
Hydrochloric Acid SCHEMBL23908611 0.77 PIK3CD (0.63) BTKPIK3CDATRABL1EGFR
SCHEMBL23908620 0.76 PIK3CD (0.77) BTKPIK3CDATRNUDT14NUDT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US claimed
EP-3057970-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Medivation Technologies, Inc. (US) 2016-08-24 EP claimed
WO-2015058084-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-04-23 WO claimed
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US disclosed
US-20210317140-A1 Heterocyclic Compounds and Methods of Use MEDIVATION TECHNOLOGIES, INC. (US) 2021-10-14 US disclosed
EP-3057970-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE Medivation Technologies, Inc. (US) 2016-08-24 EP disclosed
WO-2015058084-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE MEDIVATION TECHNOLOGIES, INC. (US) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210317140-A1 Heterocyclic Compounds and Methods of Use BTK, PIK3CD, PIK3CB BTK 1/4885PIK3CD 2/4885ATR 680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.